A.MANUFACTURER RESPONSIBLE FOR BATCH RELEASE
Name and address of the manufacturer(s) responsible for batch release
B.CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE
Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).
C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION
•Periodic safety update reports
- Irbesartan hydrochlorothiazide bms - Bristol-Myers Squibb Pharma EEIG
- Nulojix - Bristol-Myers Squibb Pharma EEIG
- Opdivo - Bristol-Myers Squibb Pharma EEIG
- Irbesartan bms - Bristol-Myers Squibb Pharma EEIG
- Sustiva - Bristol-Myers Squibb Pharma EEIG
- Baraclude - Bristol-Myers Squibb Pharma EEIG
Prescription drugs listed. Manufacturer: "Bristol-Myers Squibb Pharma EEIG"
The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines
D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
•Risk Management Plan (RMP)
The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.
An updated RMP should be submitted:
•At the request of the European Medicines Agency;
•Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.
•Obligation to conduct
The MAH shall complete, within the stated timeframe, the below measures:
In order to evaluate the recurrence of hepatocellular carcinoma associated with
Daklinza, the MAH shall conduct and submit the results of a prospective safety
study using data deriving from a cohort of a
on an agreed protocol. The final study report shall be submitted by: